Brcic, I
WuJYChenCCLing TuWHsuW-HLiuT-HTsaiY-Wet al
Funding This work was supported by the National Natural Science Foundation of China grant 82572992 (T.ZQ), the National Natural Science Foundation of China grant 82472517 (L.CQ), the National Natural Science Foundation of China grant 82203921 (L.SJ), the Guizhou Province Science and Technology Plan Project (Qiankehejichu-ZK[2024]Yiban 132 [Zuli Wang]) (W.ZL), Guizhou Provinces Scientist Workstation Project (Qiankehepingtai KXJZ [2024]004),the National Natural Science Foundation of China (82471385), Guizhou Province Scientific and Technological Innovation Talent Team Project (Qiankeherencai CXTD [2025]048) (S.M), and the Natural Science Foundation of Chongqing CSTB2024NSCQ-MSX0622 (Z.J )
Who Should Avoid Semaglutide Due to Hypoglycemia Risk Patients with type 1 diabetes or those dependent on insulin therapy should generally avoid semaglutide without close endocrinologist supervision, as the combination significantly increases hypoglycemia risk
Wearing sunscreen every day with broad spectrum protection from UVA and UVB and a sun protection factor (SPF) of 50 is not negotiable if you want dark spots to fade (and dont want new ones!)
Receptor-Binding Comparison Retatrutide and Weight Loss: What the Research Shows Phase 2 Body Weight Reduction Data (Jastreboff 2023) Phase 2 data on retatrutide weight loss first appeared in the New England Journal of Medicine in 2023
